Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hedy Teppler

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel, David A Cooper, Hedy Teppler, et al.
The New England Journal of Medicine|July 25, 2008
Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.
The New England Journal of Medicine|July 25, 2008
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel, David A Cooper, Hedy Teppler, et al.
The New England Journal of Medicine|July 25, 2008
Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.
The New England Journal of Medicine|July 25, 2008
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.
Pageof 7